TEVA - Looking for retestI would like to see this retest and then continue rising up until Earnings .
If a retest happens - I'll be looking to enter on the dip at about 21.30 or so.
T1EV34 trade ideas
DragonFly DojiTEVA, Set other cancels other order for target/stop
Target: 23.50 or higher
Stop: 19.90
Time Frame: Feb 12th
$TEVA #bottom #long #recoveryTEVA has formed a nice V bottom. Over the past few days it has stayed on its upward trend line. On the daily, weekly and monthly charts the stock looks good. My profit target is the closure of the august gap. My stop would be any break of the trend line. Why? because bottoming is a process.... that can take a long time and have many head fakes. I think this is a good company, but buying and holding good companies is not my trading style...it is my investing style....but those are two different things. My advice go long with the trade and possibly add it to your receiving dogs of the dow portfolio if you do that kind of thing.
Weekly chart
Notice Stock RSI has flatlined above 80. MACD continues to trend up. OBV is undergoing a nice recover. The price action looks good and has stayed on its trend line.
Monthly chart
Notice MACD is angling upward for an upwards cross. Stoch RSI has just shot upwards. OBV looks good
Teva strong resistence at 19.33, yet not a buyDespite the recent company's efforts to reduce its debit, from a technical point of view, I would be neutral with Teva until we will see a cross-over between slow 200d and fast 50d moving average on a daily chart pattern. For those who are aggressives MACD is still positive but keep in mind the resistence at 19.33 first and 20 after. Exhaustion gap betweeen 16 and 18 has been filled. Personally I see such movement as a prize for what the new CEO has done to reduce the impact of debit in short and mid term. Still 2018 will be critical to conferm that what has been undertaken is going toward in the right direction.
TEVA, inside day in front of exhaustion gap!TEVA was one of my favorite company to trade back to 2014-2015, and I was so bullish on the company then based on fundamental analysis~
After I stepped in the world of technical analysis and momentum trade, the story of TEVA has totally changed, too.
There was a significant "island" formed by the exhaustion gap, and here comes an inside day.
The short is the confirmation entry and the 8/21EMA correction combination; the long, on the other hand, is not a very great idea as it's fighting with the resistance.
It's a better short than long inside day case, (compared to the relative idea below-- a both sided trade)
Again, it doesn't imply I am predicting which direction it will break at all!
Link to TradingView live chart! Welcome to click it as a like button lol~
tradingview.go2cloud.org
Teva Pharmaceutical industries. up or down? This is my first wave chart, so be gentle. :)
i have 2 scenario. One is that wave 5 have ended and we are ready to a correctional wave of A,B,C.
The other is that they will present bad revenue. And the price will continue the down trend, and stop at the support line at 6,49
where the 5th wave could end and start a correction of A,B,C.
Fundamental:
Teva have a great product portfolio, but have lost 64.46% decline year to date. and a 68.83% decline from 30/10/2016 to 30/10/2017
The decline have something to do with there stock pilling on debt that run along the loss in product sales.
The U.S. generics industry is facing significant competitive and pricing pressure, which have been affecting the company’s generic revenues. An increase in FDA generic drug approvals and ongoing customer consolidation are resulting in additional competitive pressure in the industry. earlier this month, in a major blow to Teva, Mylan MYL launched its generic version of the 40 mg formulation, much earlier than expected. Mylan also launched a second generic version of Copaxone 20 mg formulation (once-daily).
Though these generic launches will not hurt Teva’s third-quarter sales and profits, Teva estimates that it will have a negative impact of at least 25 cents per share on fourth-quarter earnings.
Teva Pharmaceutical industries have a P/E Ratio (TTM)=-2,22
And a EPS(TTM)=-6,11
This means that the company is losing money.
besides that, investors now pay 2,22 Dollars less pr earned dollar
They still have a 1,20(8,07%) Forward Dividend and Yield
this means that the company is expecting a low grow rate because of the high yield
(if the Yield is low, a company is expecting high growth expectations and are more likely to give investors reward through out a rise in the stock price)
The Beta is low at 0,72. a Beta below 1 is a less volatile stock.
My target will be at 36.49$
where my stops loss will be at 6,18$
general 1y target estimate from other investors is at 20,02$
Profile:
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the womens health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinsons disease; and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders. This segments products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda/Bendeka, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. This segment also offers a portfolio of products in the womens health category, which includes ParaGard, Plan B One-Step, and OTC/Rx, as well as other products. The company has collaboration arrangements with Attenukine, Procter & Gamble Company, and Regeneron Pharmaceuticals, Inc.
(source: finance.yahoo.com)
Good luck :)
Another broken structure - Next support zone is...?TEVA broke another monthly support zone during October.
Next monthly support zone is near 13$
Where will TEVA's slide end?
Portfolio Position: Teva Pharmaceuticals $TEVATeva Pharmaceuticals $TEVA has shed over 50% of its value following its $6.1B impairment charge and 75% dividend slash in its latest quarterly report.
Pros:
- The company continues to expect double digit sales growth from its recent Actavis acquisition from Allergan $AGN.
- Teva expects over 1,500 new drugs to launch in 2017, with over 900 drugs still pending approvals.
- The company is divesting its non-core organic revenue drivers, expected to bring in over $5B in 2017 and boost margins.
- Aggressive cost cutting, saving over $1.6B annually is expected to boost Net Income and Margins.
Risks:
- Teva's blockbuster drug Copaxone is under competitive pressure, losing market share in 2017 & is expected to continue in 2018.
- Sentiment: The company still trades in a highly retail environment being effected by mass hysteria, boding bad for share price.
Targets:
I initiate TEVA with a $30 PT for the next 12 months, throughout 2018.
For the full review: seekingalpha.com
TEVA - Time to play Long!TEVA hold up last week and made a decent bull flag!
Next move up will come soon!
TEVA, A potential both-sided inside day.It's really tough for TEVA investors since 2016, everything seems so bad for this generic drugs giant.
They finally got a new CEO and got good news from FDA, which enabled the stock price to bounce 20% in 2 days.
Here we got this inside day after such a big movement, so the direction it broke becomes so important to the following sentiment on this name.
Trading this inside day directly is also an OK idea, but I would more like to find intraday trade in 5/15/30 minute chart as I don't really want to swing this name unless I have a very successful day-trade.
*For educational use only
TEVA shares moving sideways...TEVA shares moving sideways. Nonetheless, buying at a 16-18 USD level can be a good investment in the long run. I suppose the exchange rate starts moving in 15-20 usd bandwidth. This movement may take several months. We do not expect any further falls below 15 usd levels. Then, from the second half of next year, a steady wave of embarkation can start with a target price of 38.70 usd. This is about 120% of the proposed bid level.
TEVA - DEAD CAT BOUNCE is coming!TEVA is up premarket. News is out that a new CEO is taking over.
This will not change anything short term may be a year from now!
TEVA - Failed to close above the down sloping trendlineTeva had some pops in recent days. They provided good opportunities for shorting this broken name!
(4 wins and 2 losses for me on this name)
TEVA - Path to annihilation! TEVA is heading to $13.50 first and then $9.00
Any pop is a shorting opportunity!
